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Objective: Vascular closure devices (VCDs), such as the Angio-Seal, a three-component
hemostatic plug, have greatly facilitated the routine clinical practice in the catheterization
laboratory. The manufacturer recommends a local angiogram before Angio-Seal deploy-
ment. However, from the outset, we employed a simpliﬁed routine of deploying this VCD,
i.e. without use of local angiography.
Methods: The Angio-Seal was employed without a preceding femoral arteriogram over 8
years in 2074 consecutive patients, 72% presenting with acute coronary syndromes and
subjected to coronary angiography (n = 1032) or PCI n = 1042) via a transfemoral approach
with use of heparin and dual antiplatelet therapy.
Results: Deployment of the VCD was successful in 99.4%. Complete hemostasis was obtained
in 98% of cases. In 14 patients, Angio-Seal deployment failed. Mean time for placement
of Angio-Seal was <1 min, to-hemostasis 1 min, and to-mobilization 3 h. Only 3 (0.15%)
patients had a major complication with vessel occlusion that required emergent vascular
surgery with a successful outcome. Two patients developed a local pseudoaneurysm treated
with ultrasonography-guided compression. Six small and 4 large inguinal hematomas (one
requiring blood transfusion) and 5 cases of retroperitoneal bleeding (one requiring blood
transfusion) were recorded.
Conclusion: Deployment of Angio-Seal without use of local angiography was efﬁcacious
and safe, characterized by a high success rate of deployment and hemostasis with few
correctable complications in a large patient cohort undergoing transfemoral catheterization
for PCI and non-PCI procedures under anticoagulation and antiplatelet drug therapy. VCD
reduced the time-to-hemostasis and time-to-mobilization and minimized the incidence
of complications.
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Vascular closure devices (VCDs) have an increasingly impor-
tant role in the catheterization laboratory during coronary
angiography and percutaneous coronary interventions (PCI),
as an alternative to manual or mechanical compression.1–3 Of
course, nowadays, VCDs have a great competitor of growing
importance, i.e. the radial access.4 Nevertheless, their use
offers expedience, safety, patient convenience and early
ambulation, and reduced hospital resources and costs. Ample
experience has been obtained in our laboratory with routine
use of such a device, Angio-SealTM (St. Jude Medical, St. Paul,
MN, USA), for femoral artery puncture site closure and
hemostasis. Angio-Seal consists of three resorbable compo-
nents, a polymer anchor, the collagen plug, and a suture,
which are introduced with the aid of a delivery system and seal
the arterial puncture site. The manufacturer recommends that
before considering Angio-Seal use, a femoral angiogram of the
site is indicated. However, a local angiogram increases the
amount of radiation exposure, particularly important for the
groin area exposure in younger patients, as well as the load of
intravascularly administered contrast with its attendant
consequences, especially in older diabetic patients or patients
with renal insufﬁciency. From the outset, we employed a
simpliﬁed routine for the deployment of the VCD, i.e. without
use of local angiography and herein report the results of this
approach in a large cohort of patients undergoing transfemoral
catheterization.
2. Patients and methods
2.1. Patients
Over the last 8 years, the Angio-Seal VCD was employed in
2074 consecutive patients who were submitted to catheteriza-
tion by our team of 3 operators via a transfemoral approach
in order to perform coronary angiography, renal percutaneous
angioplasty, aortography, or PCI. Patients (n = 90) were
excluded when transfemoral access was considered problem-
atic or impossible due to peripheral vascular disease, requiring
a transradial approach or deemed as best suited for manual
compression rather than use of a VCD; also patients
catheterized during periods when the VCD was not available
for use in our catheterization laboratory due to a limited
supply from the manufacturer were not included in this
series. Possible complications and risks, as well the beneﬁts
of each procedure were all made explicit to the patient and
the patient's family, and informed written consent was
obtained from the patient before the procedure.
2.2. Vascular access
Vascular access was routinely obtained via puncture of the
right femoral artery and occasionally via the left femoral artery
in cases where vascular access problem was anticipated or
encountered from the right femoral artery or when repeat
access was required within a short period after puncture of
the right femoral artery.Selection of the entry site was guided most commonly by a
combination of external anatomical landmarks. Usually, the
artery was entered 2–3 cm below the midpoint of the inguinal
skin crease or at the midpoint between the anterior superior
iliac spine and pubic tubercle, guided by palpation of the
maximal arterial pulse. One operator mostly used the
ﬂuoroscopy-guided technique using visualization of the
femoral head in a posterior-anterior projection with the skin
puncture done at a point between the lower border and the
mid portion of the head of femur.
After adequate local anesthesia with subcutaneous xylo-
caine, arterial access was obtained with use of an 18-gauge
needle and a modiﬁed Seldinger technique with an attempt to
limit the stick to the anterior arterial wall and avoid posterior
wall puncture. A 6 French femoral sheath was routinely used
except when a demanding PCI procedure was planned, in
which case a 7 French sheath was employed. After arterial
access was secured, 2500 U of intravenous unfractionated
heparin was given.
2.3. Percutaneous coronary intervention
All patients submitted to PCI received a bolus of 7000 units of
heparin after obtaining vascular access for elective procedures
or right after completion of coronary angiography for ad hoc
PCI procedures. Additional heparin (2000 units/h) was admin-
istered for procedures lasting longer than 1 h if the activated
clotting time (ACT) could not be monitored or if ACT was
measured, heparin was given in doses needed to maintain the
ACT >300 s throughout the procedure. A variety of coronary
stents were implanted, including bare metal stents, endothe-
lial progenitor cell capture stents, micro net mesh covered
stents, and drug-eluting stents.
For pre-planned procedures an attempt was made to use
pretreatment with at least a pre-procedural 3-day regimen of
aspirin (325 mg daily) and clopidogrel (75 mg daily); for
patients not having been on aspirin or clopidogrel before
the procedure, a loading dose of 500 mg and 300–600 mg of
each medication, respectively, was given the day of the
procedure. For patients with angiographically demonstrated
intracoronary thrombi, particularly those with acute ST-
elevation myocardial infarction, or other high-risk patients,
e.g. diabetic patients receiving multiple stents, glycoprotein
IIb/IIIa inhibitors were used, including eptiﬁbatide or tiroﬁban.
2.4. Vascular closure device
When the procedure was completed, reversal of the effect of
heparin was not performed. A guidewire was introduced via
the sheath into the artery and then the sheath was removed
immediately without checking the ACT, while maintaining
pressure above the access site to ensure continued hemosta-
sis. Subsequently, the VCD was deployed over the guidewire.
The Angio-Seal vascular closure device delivery system
comprises the Angio-Seal device, an insertion sheath, an
arteriotomy locator, and a guidewire. The Angio-Seal device is
composed of an absorbable collagen sponge and a specially
designed absorbable polymer anchor that are connected by an
absorbable self-tightening suture (Fig. 1). The device seals
and interposes the arteriotomy between the anchor located
Fig. 1 – Angio-Seal has three resorbable components, a
polymer anchor, the collagen plug, and a suture, which are
introduced with the aid of a delivery system and seal the
arterial puncture site. The resorbable polymer anchor and
suture are placed within the artery and pulled back to the
entry site to secure the placement of the collagen plug just
outside the arterial wall.
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Hemostasis is achieved primarily by the mechanical means of
the anchor – arteriotomy – collagen inﬁx, which is supple-
mented by the coagulation-promoting properties of the
collagen. The device is contained in a delivery system that
stores and then delivers the absorbable components to the
arterial puncture. The 8-French Angio-Seal device was
employed for 8- or 7-French procedural sheaths and the 6-
French Angio-Seal device was used for a 6 French or smaller
procedural sheath. Three types (generations) of the Angio-Seal
VCD were employed during the study period (Angio-Seal,
Angio-Seal VIP, and Angio-Seal STS plus).
2.5. Deployment technique
Utilizing a new pair of sterile gloves and after cleansing the
groin around the sheath with betadine, the packet with the
Angioseal device was opened. First, the arteriotomy locator
was inserted into the Angio-Seal sheath aligned and snapped
in place. Then, this assembly was inserted over the guidewire
and advanced into the artery until blood squirting from the
drip hole on the locator was noted. Then, holding the insertion
sheath steady, the arteriotomy locator and guidewire were
removed. Holding the hub of the sheath in position with the
left hand, the Angioseal device was then advanced into
the sheath with the reference indicator on the device and the
hub of the sheath on the same side facing each other. Aftersnapping the Angioseal device in position, the hub of the
sheath was held with one hand and the cap of the device was
pulled away from the hub until resistance was felt, indicating
that the anchor was at the distal tip of the sheath. The device
sheath assembly was pulled in the direction of the track to
allow the anchor to get positioned against the vessel wall.
Pulling was then continued and tension maintained on the
device sheath assembly to expose the tamper, which was then
advanced into the track to compact the collagen. Once
hemostasis was achieved and resistance was felt, advancing
the tamper was stopped, the suture was cut below the clear
stop and the tamper tube was removed. The exposed loose
suture was further cut below the skin line by holding tension
on the thread. A sterile dressing was placed afterwards at the
entry site and pressure was applied for 2 min. All 3 operators
employed the same uniform technique of VCD deployment
with a short and smooth learning curve.
An attempt was made to record the time to hemostasis and
to ambulation after the deployment of the VCD. Complications
were recorded in every patient when they occurred. All data
were collected prospectively. All patients were followed
closely until discharge.
2.6. Recording of complications
The occurrence of a pseudoaneurysm, arterio-venous ﬁstula,
arterial thrombosis, need for vascular surgery, retroperitoneal
bleed, local abscess, bleeding or large (>10 cm) hematoma at
the puncture site requiring transfusion, or in-hospital death
attributed to VCD complication were considered as major
complications. Routine duplex ultrasound was not performed
to check the puncture site unless there was a clinical suspicion
of a pseudoaneurysm or a ﬁstula. A minor complication was
deﬁned as a localized allergic reaction or cellulitis or a
hematoma not requiring transfusion. Failure to anchor the
device and/or deliver the collagen to the puncture site was
recorded as VCD deployment failure.
2.7. Statistical analysis
The data are summarized as mean  standard deviation or
median (interquartile range) for continuous variables, and
count and/or proportions for categorical variables. Differences
in baseline parameters or exposure variables were determined
by 2-tailed Student's t-test or analysis of variance for
quantitative data and by chi-square statistic or Fischer's exact
test, when appropriate, for qualitative data. Data with no
normal distribution were compared with Mann–Whitney test.
The association of baseline exposure variables with major
endpoints was assessed through binary logistic regression.
Univariate logistic regression models were initially imple-
mented and subsequently signiﬁcant predictors were included
in the ﬁnal multivariable analysis. Parameters incorporated in
the ﬁnal analysis included the access site, age, gender,
diabetes, hypertension, hypercholesterolemia, smoking sta-
tus, use of IIb/IIIa agents, type (generation) of VCD, and type of
procedure (PCI vs non-PCI). Finally, a bootstrap resampling
procedure5 was used to conﬁrm optimal model selection.
Model calibration was assessed by comparing predicted
probabilities with observed probabilities. Goodness of ﬁt was
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Characteristic (ROC) curves analysis was used in order to
assess whether exposure variables could incrementally
identify increased risk for major complications. The curves
were constructed by plotting sensitivity against (1-speciﬁty)
and corresponding Area(s) Under the Curve (AUC) were
compared.
Statistical analysis was performed with STATA package,
version 11.1 (StataCorp, College Station, Texas, USA). Statisti-
cal signiﬁcance was set at p < 0.05. In terms of power
considerations, the baseline probability for incidence of the
primary endpoint was set as low as 1% and Type I error was
predeﬁned at 0.05. The recruited sample size provided 80%
power to detect a signiﬁcant change of 50% in odds of the
primary endpoint occurrence (from 1% to 1.5%) for one unit
increase in the corresponding exposure variable. Power
calculations were performed with G*Power, version 3.0.10.
3. Results
3.1. Procedural characteristics
Clinical and procedural characteristics of the study population
are described in Table 1. Of a total of 2164 patients catheterized
in our laboratory during the study period, 2074 patients
received a VCD and were included in the study. These were
1563 (75.4%) men and 511 women, aged 64.6  12.2 years
(range, 18–93). The VCD was used in two groups of patients,
1042 patients undergoing a PCI procedure and 1032 having a
non-PCI procedure (mostly coronary angiography or occasion-
ally renal angiography and/or renal artery angioplasty). Male
gender, smoking status, dyslipidemia, and impaired ejection
fraction were signiﬁcantly greater in the subgroup of subjects
allocated in the PCI group (Table 1).Table 1 – Characteristics of 2074 consecutive patients submitte
closure device.
All patients 
Patients 2074 
Men/Women 1563/511 
Age (years), mean  SD 64.6  12.2 
Clinical presentation
Acute coronary syndrome, n (%) 1.497 (71.9%) 
Risk factors
Smoking, n (%) 772 (37.2%) 
Hypertension, n (%) 1317 (63.5%) 
Dyslipidemia, n (%) 1436 (69.2%) 
DM, n (%) 606 (29.2%) 
LVEF (%) 50 (40–60) 
Access site
RFA, n (%) 1979 (95.4%) 
LFA, n (%) 90 (4.3%) 
RFA + LFA, n (%) 5 (0.2%) 
Adjuvant therapy
IIb/IIIa agents, n (%) 
DM, diabetes mellitus; LFA, left femoral artery; LVEF, left ventricular ej
femoral artery; NA, not applicable.History of diabetes mellitus (DM) was present in 606 (29.2%)
patients, of hyperlipidemia in 1436 (69.2%) patients, of
hypertension in 1317 (63.5%), while 772 (37.2%) patients were
current smokers. The majority (72%) were patients admitted
with an acute coronary syndrome (ACS). A total of 1042 (50.2%)
patients underwent a PCI procedure, which was performed ad
hoc (during the same session as coronary angiography) in 983
(94.3%) patients. PCI was performed on a mean number of
vessels of 1.3  0.6 with a mean of 2.4  1.4 lesions dilated and/
or stented. Stents were used in 1017 (97.6%) patients, bare
metal stents in 23 (3%) patients, endothelial progenitor cell
capture stents in 211 (21%) patients, and drug-eluting stents in
775 (76%) patients. The mean left ventricular ejection fraction
was 49.2  11.6% (range, 15–75%). A platelet glycoprotein IIb/
IIIa inhibitor was administered in 297 (14.3%) patients.
The right femoral artery was accessed in 1979 patients, the
left femoral artery in 90 patients, and both femoral arteries in 5
patients. The ﬁrst generation of the VCD (Angio-Seal) was
employed in the ﬁrst 244 patients, the second generation
device (Angio-Seal VIP) in 63 patients, and the latest genera-
tion device (Angio-Seal STS plus) in the subsequent 1767
patients. Successful VCD deployment was achieved in 2060
(99.3%) patients. In 14 patients (7 in each group), insertion of
the device failed partially or completely, and in all these cases,
manual compression was applied. The mean time required for
the placement of Angio-Seal was <1 min. The mean time-to-
hemostasis was also <1 min. The mean time-to-mobilization
was 3 h.
3.2. Complications
Acute occlusion of the femoral artery occurred in 3 (0.14%)
patients who required vascular surgery, which successfully
restored patency of the femoral artery by removing either
thrombotic material (n = 2) or the occluding anchor of thed to PCI or non-PCI procedures, who received a vascular
PCI Non-PCI p value
1042 1032
840/202 723/309 <0.001
64.3  12.3 64.9  12.2 0.210
902 (86.6%) 595 (57.7%) <0.001
459 (44%) 313 (30.3%) <0.001
642 (61.6%) 675 (65.4%) 0.727
779 (74.8%) 657 (63.7%) <0.001
290 (27.8%) 316 (30.6%) 0.163
55 (40–60) 50 (40–55) 0.013
988 (95.7%) 991 (95.2%)
41 (4%) 49 (4.7%)
3 (0.3%) 2 (0.2%) 0.648
297 (28.5%) NA
ection fraction; PCI, percutaneous coronary intervention; RFA, right
Table 2 – Outcome and complications in the PCI and non-PCI Groups.
Parameters All patients
(n = 2074)
PCI group
(n = 1042)
Non-PCI group
(n = 1032)
p value
Outcomes
Successful deployment, n (%) 2060 (99.4%) 99.4% 99.4% 0.999
Failed deployment, n (%) 14 (0.6%) 7 (0.6%) 7 (0.6%) 0.999
Complications
Need for local surgery, n (%) 3 (0.15%) 2 (0.19%) 1 (0.1%) 0.569
Retroperitoneal bleeding, n (%) 5 (0.24%) 4 (0.38%) 1 (0.1%) 0.183
Groin bleeding/hematoma, n (%) 10 (0.48%) 8 (0.77%) 2 (0.2%) 0.028**
Pseudoaneurysm, n (%) 2 (0.1%) 1 (0.1%) 1 (0.1%) 0.999
AV ﬁstula, n (%) 0 NA
Local infection, n (%) 0 NA
Vagotonia, n (%) 5 4 1 0.183
Rigors/Allergy, n (%) 3 3 0 0.085**
Overall complications, n (%) 28 (1.35%) 22 (2.11%) 6 (0.01%) 0.001
*In-hospital mortality, n (%) 5 (0.24%) 4 (0.38%) 1 (0.1%) 0.18
AV, arteriovenous; NA, non-applicable; PCI, percutaneous coronary intervention.
* Unrelated to VCD (see text for discussion).
** Continuity correction performed.
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patients developed a pseudoaneurysm of the right common
femoral artery; the lesion was treated with ultrasonography-
guided compression. In addition, 6 small/moderate local hema-
tomas and 4 large inguinal hematomas were recorded (Table 2);
one patient with a large hematoma required blood transfusion.  In
5 cases (4 in the PCI and 1 in the non-PCI group), retroperitoneal
bleeding occurred, requiring blood transfusion in one of them;
3 patients were receiving a IIb/IIIa inhibitor. No cases of local
infection were observed. Overall, complications were higher
( p < 0.001) in the PCI group but signiﬁcant difference in
individual categories was established only for groin hematoma.
3.3. Risk predictors
Female gender, procedure type (PCI), generation of VCD, DM
type II (marginal), and administration of IIb/IIIa were signiﬁ-
cant predictors in univariate analysis for complications after
VCD use (Table 3). Multivariate analysis indicated that femaleTable 3 – Association of baseline exposure variables with the in
regression analysis.
Variables Univariate 
Odds ratio (95% CIs) 
Age 1.023 (0.995–1.052) 
Gender (Female) 3.31 (1.75–6.25) 
Smoking (yes) 0.746 (0.376–1.48) 
Hypertension (yes) 1.3 (0.654–2.58) 
DM (yes) 0.435 (0.182–1.04) 
Dyslipidemia (yes) 1.29 (0.627–2.67) 
Type of procedure (PCI) 2.26 (1.14–4.49) 
IIb/IIIa agent administration (yes) 3.058 (1.55–6.02) 
Access site (LFA/both) 1.76 (0.532–5.81) 
Type of VCD(PLUS) 0.694 (0.15–3.22) 
(VIP) 0.316 (0.154–0.649) 
CI, conﬁdence intervals; DM, diabetes mellitus; LFA, left femoral artery; PC
Odds ratios are provided for the category of interest denoted in parenthgender (odds ratio – OR = 3.99, 95% conﬁdence intervals – CIs:
2.01–7.98; p < 0.0001), use of a IIb/IIIa agent (OR = 2.87, 95% CIs:
1.24–6.62; p = 0.014), DM (OR = 0.354, 95% CIs: 0.145–0.866;
p = 0.023), and the generation of VCD (OR = 0.361, 95% CIs:
0.168–0.776; p = 0.009) independently predicted the major
endpoint of the study. Access through the left femoral artery
(LFA) or both femoral arteries was marginally associated with
higher risk (OR = 2.45, 95 CIs: 0.878–6.81). Conversely, age,
traditional risk factors, and procedure type (PCI versus
catheterization) did not confer a higher risk. The protective
role of DM was not mediated by the exposure variables
included into the multivariable model as indicated by the lack
of statistical signiﬁcance of all interaction terms that were
tested (exposure variables in Table 3 *DMII, p > 0.05 for all). In a
subgroup of patients with data for left ventricular ejection
fraction (LVEF) available (n = 644), a multivariable model
identical to Table 3 plus LVEF at baseline (OR = 0.987, 95%
CIs: 0.94–1.04, p = 0.611) indicated a non-signiﬁcant association
of DMII (OR = 0.408, 95% CIs: 0.08–2.15; p = 0.291) with risk ofcidence of major complications in our study through logistic
Multivariable
p-value Odds ratio (95% CIs) p-value
0.103 1.019 (0.989–1.05) 0.25
<0.001 3.99 (2.01–7.98) <0.001
0.402 0.852 (0.381–1.9) 0.696
0.454 1.18 (0.571–2.46) 0.649
0.062 0.354 (0.145–0.866) 0.023
0.485 1.03 (0.485–2.19) 0.938
0.02 1.8 (0.81–3.98) 0.149
0.001 2.87 (1.24–6.62) 0.014
0.354 2.45 (0.878–6.81) 0.087
0.641 0.448 (0.9–2.26) 0.326
0.002 0.361 (0.168–0.776) 0.009
I, percutaneous coronary intervention; VCD, vascular closure device.
eses below the column ‘‘Variables’’.
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predictors (female gender, IIb/IIIa use and type of VCD,
p < 0.05) and might suggest a residual unadjusted confounder.
When additional adjustment for peripheral artery disease
(OR = 2.39, 95 CIs: 0.56–10.22; p = 0.240) was performed,Fig. 2 – Receiver operator curves (ROC) for main predictors of: (A
Area Under the Curve (AUC) for each parameter of interest is pro
<0.05 denote significant difference of AUC from 0.5 (under the nuindependent predictors for higher risk of complications
retained their statistical signiﬁcance (gender, DM, IIb/IIIa
and generation of VCD, p < 0.05 for all three). Relevant results
were established when alternative confounders, not indicated
by univariate analysis or the bootstrap technique, were) total complications; (B) major complications in our study.
vided in median value (95% confidence intervals). P-values
ll hypothesis the true AUC is 0.5 for classification variables).
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urgent/emergent versus elective catheterization, number of
lesions/vessels dilated and/or stented neither impoverished
the aforementioned associations with gender, IIb/IIIa use, VCD
generation and DM ( p < 0.05 for all) nor established new
predictors ( p > 0.05 for all). When the endpoint of complica-
tions was limited for major adverse events only, relevant
logistic regression analysis did not substantially alter our
results. Female gender (OR = 9.28, 95 CIs: 3.13–27.5; p < 0.001),
IIb/IIIa administration (OR = 3.43, 95 CIs: 1.022–11.5; p = 0.046),
and VCD generation (OR = 0.204, 95 CIs: 0.072–0.58; p = 0.003)
were the only independent predictors of complications after
VCD use. DMII remained a marginal protective predictor
(OR = 0.135, 95 CIs: 0.017–1.05; p = 0.056) for major complica-
tions. All the additional adjustments (urgent/emergent versus
elective catheterization, number of lesions/vessels) did not
change the main associations described above. As with
extended complications, adjustment for LVEF in 644 subjects
rendered the association of DMII with decreased risk not
signiﬁcant (OR = 0.658, 95 CIs: 0.058–7.45; p = 0.736).
Among exposure variables, female gender increased most
the odds of presenting a complication with VCD use. After
adjusting for all major confounders, female subjects had a 4-
fold increase in all adverse events and a 9-fold increase in
major complications in comparison to male subjects. Table 2
summarizes non-parametric ROC analysis in terms of AUC
that correspond to each baseline predictor. In both endpoints,
gender was associated with signiﬁcantly increased AUC but
relative differences with AUC corresponding to other pre-
dictors were not established (Fig. 2). An incremental predictive
role was not established for none of female gender, VCD
generation, DM, and IIb/IIIa use when AUCs for nested
multivariable models were compared (e.g. AUC of multivari-
able model without gender versus AUC of full model, p > 0.05
for all comparisons).
3.4. In-hospital mortality
During hospitalization, 5 patients, 4 (0.38%) in the PCI and 1 (0.1%)
in the non-PCI group, succumbed to their disease. There was
no apparent relation to use of the VCD. No local vascular
complication was noted in any of the 4 PCI patients. One death
occurred suddenly 8 h after successful PCI of the left circumﬂex;
one death occurred in an elderly patient 3 days after PCI of a
saphenous vein graft complicated by no-reﬂow; one heart
failure death occurred in a nonagenarian patient 2 days after
successful PCI of two vessels; one patient sustained a new fatal
anterior myocardial infarction 3 days after a complicated PCI of
a saphenous vein graft to the left circumﬂex; ﬁnally, a heart
failure death occurred in one elderly patient with mitral stenosis,
non-signiﬁcant coronary artery disease and compromised left
ventricular function 2 weeks after coronary angiography; this
patient developed retroperitoneal hematoma post-procedurally;
however, she did not require any blood transfusion.
4. Discussion
The present study demonstrates in a series of 2074 consecutive
patients of three operators' experience that the AngioSeal wasa very effective VCD, with a 99.3% successful deployment rate,
in a swift and simple procedure obviating the need for
performance of local angiography to guide deployment. A
local angiogram increases both the duration of radiation
exposure, particularly important for the groin area exposure in
younger patients, as well as the load of intravascularly
administered contrast with its attendant risks, especially in
older diabetic patients or patients with renal insufﬁciency,
which can all be potentially avoided with use of our suggested
approach. These results are, of course, commensurate with the
ability to perform an arterial puncture at the appropriate site,
which is considered to be the common femoral artery.1 Thus,
avoiding low femoral arterial entry or puncture above the
inguinal ligament was apparently of critical importance. This
was achieved by use of external and/or ﬂuoroscopic landmarks
and a modiﬁed Seldinger's technique, but without use of
femoral angiography.
The mechanical seal achieved with Angio-Seal (Fig. 1)
produces virtually immediate hemostasis, allowing the pro-
cedure to be completed in the catheterization laboratory. The
three components of this VCD, suture, collagen, and anchor,
used to seal the puncture site, are fully resorbable within 60–90
days. Immediate repeat puncture of the artery, if and when
needed, is safe to perform without an increased risk of
vascular complications.
The reasoning behind the instruction of the manufacturer
to use a local angiogram to guide VCD deployment relates to
avoidance of complications (http://www.pei.ie/PEI/media/
PEI-media/PDFs/PDFs_Cardiac/PDFs_Cardiac_Products/
angio-seal_evolution_ifu_us.pdf). Thus, the recommendation
is not to use the Angio-Seal device if the procedure sheath has
been placed through the superﬁcial femoral artery and into the
profunda femoris as this may result in collagen being placed
into the superﬁcial femoral artery, leading to arterial throm-
bosis and symptoms of acute distal ischemia. In the same line,
the Angio-Seal device should not be used if the puncture site is
at or distal to the bifurcation of the superﬁcial femoral and
profunda femoris artery, as this may result in the anchor
entrapped in the bifurcation or being positioned incorrectly,
and/or collagen deposition into the vessel, all potentially
leading to vessel occlusion. Lastly, the Angio-Seal device
should not be used if the puncture site is proximal to the
inguinal ligament as this may result in retroperitoneal
bleeding.
All these important issues were taken into consideration in
the present study and the operators made a conscious attempt
to puncture the artery at the optimal site, i.e. above the
bifurcation and below the inguinal ligament, albeit without the
use of local angiography, in order to avoid all these pitfalls. In
addition, an attempt was made to limit the arterial puncture to
the anterior wall of the artery and thus avoid deep tissue and/
or retroperitoneal bleeding. The technique employed appar-
ently rendered this feasible as inferred by the results of the
present study, whereby the complication rate was kept to a
minimum with 3 (0.15%) patients suffering from vessel
occlusion requiring surgery.
Historically, femoral arterial access for various catheteri-
zation procedures has necessitated prolonged (≥20–30 min)
manual or mechanical compression and extended (≥6–12 h)
bed rest following sheath removal.1,6,7 Progressively, however,
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have ushered in a new era in clinical practice allowing for
faster hemostasis at the puncture site, and early ambulation
and shorter hospital stay for patients undergoing transfe-
moral interventional procedures.1,3,8 VCDs are characterized
mainly by the mechanism of hemostasis they provide, which
includes biodegradable collagen or other plug, staples, or
sutures.9 However, despite the apparent advantages of VCDs,
complications at the site of femoral artery access still
occur.10,11 Newer generation devices appear more promising
with improved safety proﬁle.12 This was also the case in the
present study where the newer generation VCD performed
better compared to older VCD types. However, due to reports
of early failure of even more recent versions of VCD,13,14 our
group avoided the use of this particular model. The need
for more efﬁcacious hemostasis is greater for patients
undergoing PCI procedures, whereby heavy antithrombotic
and anticoagulant therapy has been employed. During such
demanding procedures, reversal of the coagulant effect is
usually avoided due to risk of coronary vessel occlusion
and/or stent thrombosis, and sheath removal is deferred,
occasionally for several hours,8 for the anticoagulant
effect to dissipate (e.g. until the measured ACT drops below
180–200 s) and thus reduce the risk of bleeding before
manual compression can be successfully applied on the
puncture site.
Several trials have examined the efﬁcacy and safety of
VCDs,1,10,15 but there is still lack of strong data from
randomized clinical trials establishing the superiority of VCDs
over manual or mechanical compression.16 For both diagnostic
and PCI procedures, VCDs are effective and more practical over
manual compression, offering more rapid hemostasis and
earlier ambulation over manual compression, successfully
competing with the transradial approach. Among the poten-
tial shortcomings of VCDs, deployment failure is a major
issue,17 but more important are the local vascular complica-
tions that may ensue, which may lead to leg ischemia and/or
need for vascular surgery with its attendant risks.18 Data from
earlier meta-analyses have cast doubts whether vascular
complications were any different between mechanical com-
pression and VCDs; they even suggested some potential
harm.2,10,19 The argument that has been put forth relates to
inclusion in these analyses of data from use of earlier
generation of VCDs, which have been subsequently with-
drawn from the market. When such data are excluded from
the analysis, the results become neutral. Furthermore,
additional meta-analysis19 has indicated a signiﬁcant 11%
reduction in vascular complications from 16 PCI studies
comprising 5048 patients. More recently, an analysis of the
ACUITY trial examining the impact of VCDs and antithrom-
botic therapy on local bleeding complications showed a
signiﬁcant decrease in major local bleeding associated with
VCD use.20 Similar ﬁndings were obtained from a Northern
New England PCI registry comprising more than 45,000
patients,21 and an analysis of the National Cardiovascular
Data Registry database comprising more than 1.5 million
patients,22 which showed that both bleeding-avoidance
strategies of VCD and bivalirudin use resulted in signiﬁcant
reductions in local bleeding complications. Patients at
higher-risk for bleeding had the greatest beneﬁt from use ofVCDs. These results compare favorably with reported rates of
bleeding via the transradial approach.4,23
It appears that VCD use may ﬁnally be operator-dependent
despite that the learning curve appears to be relatively short.
Integration of clinical data, having performed the arterial
puncture at the correct site and familiarizing oneself with a
particular VCD, seems to play a key role in successfully
deploying the device and achieving complete hemostasis and
avoiding disastrous local complications.24 Deployment of
older generation VCDs was cumbersome and beneﬁts were
not that apparent compared with manual compression,
particularly with regard to safety.2,15,25,26 However, newer
generation devices have overcome such limitations and have
contributed to reduced local complication rate.16,27
In the present study, we have demonstrated a high (99.4%)
success rate of initial deployment of the VCD with also a high
(98%) rate of successful ﬁnal hemostasis in a large population
of high-risk patients with the majority presenting with acute
coronary syndromes undergoing PCI procedures via a transfe-
moral approach. Use of anticoagulation and/or strong anti-
platelet therapy with IIb/IIIa inhibitors on top of dual
antiplatelet therapy led, as it might have been expected, to
higher, albeit not inordinate, local complication rate. In
contrast, only 2 patients sustained major bleeding (inguinal
or retroperitoneal) requiring blood transfusion, and only two
additional patients developed a local pseudoaneurysm treated
conservatively with ultrasound-guided compression.
4.1. Predictors of local complications
According to the results of the multivariable analysis in our
population, female gender, the presence of diabetes, use of a
IIb/IIIa agent, and generation of VCD predicted major and total
complications. Conversely, age, and traditional risk factors did
not confer a higher risk. A higher complication rate with use of
VCDs in women has been previously reported and ascribed to
smaller arterial luminal diameters in women.28
4.2. Study limitations
Although this is a prospective study, it lacks randomization
with a control group of patients having manual compression
during the same time period. This is because a VCD was
employed systematically in all consecutive patients undergo-
ing a catheterization procedure during the study period, except
for brief periods when the device was not available or when
there were patients having peripheral vascular disease who
had the procedure done via a radial or brachial approach, and
thus there was no comparable group having concurrent
manual compression. The lack of 30-day follow-up in this
patient population may be considered as another limitation of
the present study, but it has been demonstrated by other
studies that most of the adverse events (95.5%) occur during
hospitalization.16
5. Conclusion
As a bleeding avoidance strategy, Angio-Seal was an efﬁca-
cious and safe VCD characterized by a high (99.4%) success rate
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successful hemostasis (98%), with few (1.4%) correctable
complications in a very large patient population undergoing
transfemoral catheterization for PCI and non-PCI procedures
under anticoagulation and antiplatelet drug therapy. In these
patients, VCD reduced the time-to-hemostasis and time-to-
mobilization and minimized complications. Further random-
ized studies16 are needed to more deﬁnitively determine
efﬁcacy and safety, and examine issues of cost-effectiveness8
of the transfemoral approach over manual or mechanical
compression. More importantly, studies, such as the an-
nounced ARISE trial,29 are needed to compare the transfemoral
access routinely using a VCD with the radial approach in terms
of speed, effectiveness, safety, and cost-efﬁcacy.30
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